As CEO, responsible for managing a leading global small molecule contract development & manufacturing business supplying drug substances, drug products, and testing services to the innovator and generic pharmaceutical markets. Cambrex has 12 sites in North America and Europe with over 2100 employees. Cambrex generated approximately $650 million in revenues in 2019. On August 7, 2019, Cambrex, a NYSE listed company announced that it signed a definitive agreement to be acquired by an affiliate of the Permira funds in a public to private transaction valued at approximately $2.4 billion including net debt. The transaction closed in December 2019 and Cambrex shareholders received $60.00 in cash which represented a 47% premium to the August closing price.